GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zenith Capital Corporation (TSXV:ZENI.P) » Definitions » 3-Year FCF Growth Rate

Zenith Capital (TSXV:ZENI.P) 3-Year FCF Growth Rate : -39.70% (As of Jan. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Zenith Capital 3-Year FCF Growth Rate?

Zenith Capital's Free Cash Flow per Share for the three months ended in Jan. 2024 was C$-0.03.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -39.70% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 59.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 6 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Zenith Capital was 82.80% per year. The lowest was -39.70% per year. And the median was 69.00% per year.


Competitive Comparison of Zenith Capital's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Zenith Capital's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zenith Capital's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zenith Capital's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Zenith Capital's 3-Year FCF Growth Rate falls into.



Zenith Capital 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Zenith Capital  (TSXV:ZENI.P) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Zenith Capital 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Zenith Capital's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Zenith Capital (TSXV:ZENI.P) Business Description

Traded in Other Exchanges
N/A
Address
2475 Queens Avenue, West Vancouver, BC, CAN, V7V 2Y9
Zenith Capital Corporation is a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics for the treatment of cancer and other disorders with significant unmet medical needs. The company is developing various novel combinations of BET inhibitors with other targeted agents. The lead compound, ZEN-3694, is in clinical development for mCRPC in combination with androgen receptor inhibitor, XTANDI, with Astellas and Newsoara as collaborators; triple-negative breast cancer in combination with the PARP inhibitor TALZENNA with Pfizer as a collaborator; androgen receptor independent mCRPC in combination with immune checkpoint inhibitor KEYTRUDA and XTANDI with University of California, San Francisco as a collaborator.

Zenith Capital (TSXV:ZENI.P) Headlines

No Headlines